Drostanolone propionate
From Wikipedia, the free encyclopedia
Drostanolone propionate
|
|
Systematic (IUPAC) name | |
(2R,5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-2,10,13-trimethyl-1,2,4,5,6,7,8,9,
11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one |
|
Identifiers | |
CAS number | |
ATC code | A14 |
PubChem | |
Chemical data | |
Formula | C23H36O3 |
Mol. mass | 360.53 g/mol |
SMILES | & |
Pharmacokinetic data | |
Bioavailability | Oral 0-2%, Intramuscular 100% |
Protein binding | highly |
Metabolism | hepatic |
Half life | ? |
Excretion | renal |
Therapeutic considerations | |
Pregnancy cat. |
X |
Legal status | |
Routes | Intramuscular injection or transdermal cream |
Drostanolone (trade name Masteron) is an anabolic/androgenic steroid. It is known to be highly androgenic and mildly anabolic. It is incapable of aromatization and has similar properties to dihydrotestosterone. It has been successfully used as a breast cancer drug but because of the high risk of virilization safer options are prescribed.
[edit] Use in sports
Masteron is used primarily by athletes who need to retain strength while losing mass. It is beneficial to runners and athletes who must remain in a certain weight class. It has gained popularity in the bodybuilding community as a diuretic and muscle defining drug.
[edit] Trivia
Ultimate Fighting Championship athlete Hermes Franca tested positive for use of Drostanolone following his July 7th 2007 lightweight championship bout against title holder Sean Sherk.
[edit] References
http://www.mmaweekly.com/absolutenm/templates/dailynews.asp?articleid=4359&zoneid=13 See it was Sherk
- Eur J Cancer Clin Oncol. 1983 Sep;19(9):1231-7.
- Cancer Res. 1982 Nov;42(11):4408-12 Marin P, Oden B, and Bjorntorp P. Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: effects of androgens. J Clin Endocrinol Metab 80: 239-243, 1995
- Sem Hop. 1982 Sep 23;58(34):1919-23.
|